RxDoctor Payments DataLook up a doctor →

Rafael Fonseca, MD

Hematology · Scottsdale, AZNPI 1275517898

Payments from drug & device makers

$2,440,899in general payments, 2019–2025

Across 434 payments — averaging $5624.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$1.4M
  • Pfizer$225K
  • AstraZeneca$169K
  • Janssen Global Services, LLC$109K
  • Bristol Myers Squibb$77K
  • Sanofi$70K
  • plus $390K from 21 others
$9,273in research payments, 2019–2025

Across 10 payments — averaging $927.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$5K
  • Pfizer$3K
  • F. Hoffmann-la Roche AG$1K

What the payments were for

  • Consulting fees$496,23976%
  • Speaking & faculty fees$109,19117%
  • Travel & lodging$38,4226%
  • Food & beverage$6,3361%
  • Education$3060%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$34,772
Medicare patients
145
Services billed
298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide108$1,870,980
PomalystPomalidomide61$1,308,396
VenclextaVenetoclax27$328,916
Lenalidomide21$274,507
BrukinsaZanubrutinib13$86,134
EliquisApixaban27$14,631
Acyclovir169$2,948
Fentanyl12$1,549
Dexamethasone44$581
Oxycodone Hcl20$549
Morphine Sulfate ErMorphine Sulfate20$363
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim42$299
Prochlorperazine Maleate14$167
Ondansetron Hcl20$164
Alprazolam16$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$76,664$1,870,980108 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$32,692$1,308,39661 claims
AbbVieVenclexta$15,311$328,91627 claims
PfizerEliquis$225,083$14,63127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Arizonaon file to place this against a meaningful peer group, so we don't.

Other hematology in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →